istisociclib
Phase 1/2- Indications
- Ovarian cancer
Company intelligence / Profile preview
Kronos Bio, Inc.
San Mateo, California, United States of Americakronosbio.com ↗
- Ownership
- Public · KRON
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
The company discontinued its clinical trial for istisociclib (KB-0742) in November 2024 due to adverse events and an unfavorable benefit-risk profile in treating platinum-resistant high-grade serous ovarian cancer. The company has suspended clinical, research, and development activities while evaluating strategic alternatives.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Genentech
Beyond the preview
Go deeper on Kronos Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kronos Bio, Inc..